These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 21145508)

  • 21. Lactic acidosis: relationship between metformin levels, lactate concentration and mortality.
    Boucaud-Maitre D; Ropers J; Porokhov B; Altman JJ; Bouhanick B; Doucet J; Girardin E; Kaloustian E; Lassmann Vague V; Emmerich J
    Diabet Med; 2016 Nov; 33(11):1536-1543. PubMed ID: 26882092
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risk of lactic acidosis or elevated lactate concentrations in metformin users with renal impairment: a population-based cohort study.
    Eppenga WL; Lalmohamed A; Geerts AF; Derijks HJ; Wensing M; Egberts A; De Smet PA; de Vries F
    Diabetes Care; 2014 Aug; 37(8):2218-24. PubMed ID: 24842984
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus.
    Salpeter S; Greyber E; Pasternak G; Salpeter E
    Cochrane Database Syst Rev; 2002; (2):CD002967. PubMed ID: 12076461
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lactate levels in Asian patients with type 2 diabetes mellitus on metformin and its association with dose of metformin and renal function.
    Lim VC; Sum CF; Chan ES; Yeoh LY; Lee YM; Lim SC
    Int J Clin Pract; 2007 Nov; 61(11):1829-33. PubMed ID: 17887995
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Metformin reduces systemic methylglyoxal levels in type 2 diabetes.
    Beisswenger PJ; Howell SK; Touchette AD; Lal S; Szwergold BS
    Diabetes; 1999 Jan; 48(1):198-202. PubMed ID: 9892243
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of Japanese regulatory action on metformin-associated lactic acidosis in type II diabetes patients.
    Hanatani T; Sai K; Tohkin M; Segawa K; Saito Y
    Int J Clin Pharm; 2015 Jun; 37(3):537-45. PubMed ID: 25822043
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The safety and pharmacokinetics of metformin in patients with chronic liver disease.
    Smith FC; Stocker SL; Danta M; Carland JE; Kumar SS; Liu Z; Greenfield JR; Braithwaite HE; Cheng TS; Graham GG; Williams KM; Day RO
    Aliment Pharmacol Ther; 2020 Mar; 51(5):565-575. PubMed ID: 31960986
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Contraindications can damage your health--is metformin a case in point?
    Holstein A; Stumvoll M
    Diabetologia; 2005 Dec; 48(12):2454-9. PubMed ID: 16283245
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Acute kidney injury, plasma lactate concentrations and lactic acidosis in metformin users: A GoDarts study.
    Connelly PJ; Lonergan M; Soto-Pedre E; Donnelly L; Zhou K; Pearson ER
    Diabetes Obes Metab; 2017 Nov; 19(11):1579-1586. PubMed ID: 28432751
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lactic acidosis in metformin therapy.
    Lalau JD; Race JM
    Drugs; 1999; 58 Suppl 1():55-60; discussion 75-82. PubMed ID: 10576527
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial.
    Schernthaner G; Matthews DR; Charbonnel B; Hanefeld M; Brunetti P;
    J Clin Endocrinol Metab; 2004 Dec; 89(12):6068-76. PubMed ID: 15579760
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Metformin monitoring and change in serum creatinine levels in patients undergoing radiologic procedures involving administration of intravenous contrast media.
    Parra D; Legreid AM; Beckey NP; Reyes S
    Pharmacotherapy; 2004 Aug; 24(8):987-93. PubMed ID: 15338847
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adverse event notifications implicating metformin with lactic acidosis in Australia.
    Huang W; Castelino RL; Peterson GM
    J Diabetes Complications; 2015; 29(8):1261-5. PubMed ID: 26104729
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Traditional contraindications to the use of metformin -- more harmful than beneficial?].
    Holstein A; Egberts EH
    Dtsch Med Wochenschr; 2006 Jan; 131(3):105-10. PubMed ID: 16418951
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety of metformin in patients with chronic obstructive pulmonary disease and type 2 diabetes mellitus.
    Hitchings AW; Archer JR; Srivastava SA; Baker EH
    COPD; 2015 Apr; 12(2):126-31. PubMed ID: 25938184
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Population exposure-response modeling of metformin in patients with type 2 diabetes mellitus.
    Hong Y; Rohatagi S; Habtemariam B; Walker JR; Schwartz SL; Mager DE
    J Clin Pharmacol; 2008 Jun; 48(6):696-707. PubMed ID: 18372428
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [How I treat ... with metformin a diabetic patient with moderate renal insufficiency].
    Scheen AJ
    Rev Med Liege; 2013 Apr; 68(4):190-5. PubMed ID: 23755710
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Safety of metformin in the treatment of elderly type 2 diabetes mellitus].
    Tian H; Li CL; Yang G; Wang YZ; Zong WY; Shao YH; Yan ST; Li J; Huang JH; Gong YP; Liu MY
    Zhonghua Nei Ke Za Zhi; 2008 Nov; 47(11):914-8. PubMed ID: 19080232
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Metformin therapy in patients with chronic kidney disease.
    Duong JK; Roberts DM; Furlong TJ; Kumar SS; Greenfield JR; Kirkpatrick CM; Graham GG; Williams KM; Day RO
    Diabetes Obes Metab; 2012 Oct; 14(10):963-5. PubMed ID: 22564555
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.